The Galien Forum USA 2020

PANEL
3

Co-Moderators
Pr. Sue Desmond-Hellmann, MD, MPh
Former Chief Executive Officer
Bill & Melinda Gates Foundation, Seattle, WA

Committee Chair, Prix Galien USA
Co-Chair, Galien Forum

Dr. Michael Rosenblatt
Co-Chair, Galien Forum
Committee Member, Prix Galien USA

Chief Medical Officer
Flagship Pioneering, Cambridge, MA

Panelists
Kenneth C. Frazier
Chairman of the Board, President and Chief Executive Officer
Merck & Co., Inc.

Betsy Nabel, MD
President
Brigham Health

Michel Vounatsos
Chief Executive Officer
Biogen

Panel Intro

The Next 50 Years of Innovation: Where Will It Come From and How Do We Secure It?(CEOs panel)


Susan_Desmond-Hellmann_P3 Co-Moderator
Pr. Sue Desmond-Hellmann, MD, MPh
Former Chief Executive Officer
Bill & Melinda Gates Foundation, Seattle, WA
Committee Chair, Prix Galien USA
Co-Chair, Galien Forum

Susan D. Desmond-Hellmann is a physician scientist who has spent the past four decades as an innovator and leader in life sciences. Dr. Desmond-Hellmann most recently served as the Chief Executive Officer of Bill & Melinda Gates Foundation, stepping down in January 2020 to become Senior Advisor and Board Member of the Gates Medical Research Institute. She joined the Board of Directors of Pfizer April, 2020, and began serving as Senior Advisor Google Ventures in May 2020. She has served as a Senior Advisor at BDT Capital, LLC, a private investment firm, since October, 2017. Prior to joining The Gates Foundation in May 2014, she was the Chancellor at University of California, San Francisco (UCSF) 2009-2014 where she remains an Adjunct Professor. From 2004 through 2009, Dr. Desmond-Hellmann served as President of Product Development at Genentech, where she was responsible for pre-clinical and clinical development, business development, and product portfolio management. She joined Genentech in 1995. Prior to joining Genentech, Dr. Desmond-Hellmann was associate director of clinical cancer research at Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Desmond-Hellmann previously served as a member of the board of directors of Facebook 2013-2019 and The Procter & Gamble Company 2010-2016. Dr. Desmond-Hellmann holds a B.S. in Pre-Med and an M.D. from the University of Nevada, Reno, and an M.P.H. from the University of California, Berkeley. She is board certified in Internal Medicine and Medical Oncology.


Michael_Rosenblatt_P3 Co-Moderator
Dr. Michael Rosenblatt
Co-Chair, Galien Forum
Committee Member, Prix Galien USA
Chief Medical Officer
Flagship Pioneering, Cambridge, MA

Dr. Michael Rosenblatt’s career has been in academia, pharma and biotech/venture. He is a physician—scientist, now serving as Chief Medical Officer of Flagship Pioneering in Cambridge, MA, a firm that originates new biotech companies. Previously, he was Merck’s Chief Medical Officer. He also served as Dean of Tufts University School of Medicine, and before that, Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. He was President of Beth Israel Deaconess Medical Center and Director of the Harvard-MIT Division of Health Sciences and Technology. He graduated summa cum laude from Columbia, and received his M.D. magna cum laude from Harvard. Internship, residency, and endocrinology training were all at the Massachusetts General Hospital.


Kenneth_Frazier_P3Kenneth C. Frazier
Chairman of the Board, President and Chief Executive Officer
Merck & Co., Inc.

Kenneth C. Frazier has served as the Chairman of the Board, President and Chief Executive Officer of Merck & Co., Inc. since 2011. Under Ken’s leadership, Merck is delivering innovative lifesaving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders.  Ken has substantially increased Merck’s investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide benefit to society.  He has also led the formation of philanthropic and other initiatives that build on Merck’s 125-year plus legacy.

Ken joined the company in 1992 and has held positions of increasing responsibility including General Counsel and President.  Prior to joining Merck, Ken was a partner with the Philadelphia law firm of Drinker Biddle & Reath.  Ken’s contributions, especially in the legal, business and humanitarian fields, have been widely recognized. He sits on the boards of PhRMA, Weill Cornell Medicine, Exxon Mobil Corporation, Catalyst and Cornerstone Christian Academy in Philadelphia, PA.  He also is a member of the American Academy of Arts and Sciences, the American Philosophical Society, The Business Council, the Council of the American Law Institute, and the American Bar Association.  Additionally, Ken is co-chair of the Legal Services Corporation’s Leaders Council.

Ken received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.


Elisabeth NabelBetsy Nabel, MD
President
Brigham Health

Betsy Nabel is President of Brigham Health and Professor of Medicine at Harvard Medical School since 2010. Nabel’s diverse experience as a physician, research scientist, executive, and advocate has molded her vision for the future of academic medicine. At Brigham Health, Nabel is leading organizational transformation focused on innovation and building a collaborative culture to reshape healthcare delivery, compassionate care, scientific discovery, and training the next generation of medical and scientific leaders. 2005-2009, she directed the NIH National Heart, Lung, and Blood Institute, leveraging the $3 billion research portfolio to establish pioneering scientific programs in genomics, stem cells, and translational research. Betsy was named one of the nation’s top leaders in medicine by Modern Healthcare and Boston Magazine. She’s a member of the American Academy of the Arts & Sciences, and the National Academy of Medicine. Nabel serves on the boards of Medtronic, the Broad Institute, the BGCB, and the Lasker Foundation.


Michel_Vounatsos_P3Michel Vounatsos
Chief Executive Officer
Biogen

Michel Vounatsos has been Chief Executive Officer (CEO) of Biogen and a member of its Board of Directors since January 2017. He joined the company in 2016 as Executive Vice President, Chief Commercial Officer.
Under Mr. Vounatsos’ direction, Biogen is pursuing its strategy as a leader in neuroscience as well as adjacent therapeutic areas, underpinned by the belief that neurological diseases and treatment strategies are interconnected.
Prior to joining Biogen, Mr. Vounatsos had a 20-year career at Merck and has additionally held management positions at Ciba-Geigy.
Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.